MYGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Myriad Genetics's Net Income for the three months ended in Dec. 2023 was $-31.2 Mil. Myriad Genetics's Revenue for the three months ended in Dec. 2023 was $196.6 Mil. Therefore, Myriad Genetics's net margin for the quarter that ended in Dec. 2023 was -15.87%.
The historical rank and industry rank for Myriad Genetics's Net Margin % or its related term are showing as below:
The historical data trend for Myriad Genetics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | 0.54 | -31.24 | -3.94 | -16.51 | -34.96 |
Myriad Genetics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Net Margin % | Get a 7-Day Free Trial | -23.79 | -30.19 | -63.27 | -31.94 | -15.87 |
For the Diagnostics & Research subindustry, Myriad Genetics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Myriad Genetics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -263.3 | / | 753.2 | |
= | -34.96 % |
Myriad Genetics's Net Margin for the quarter that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | -31.2 | / | 196.6 | |
= | -15.87 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (NAS:MYGN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Myriad Genetics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Bryan Riggsbee | officer: Chief Financial Officer | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Daniel K Spiegelman | director | MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
Heinrich Dreismann | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Nicole Lambert | officer: Chief Operating Officer | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Margaret Ancona | officer: SVP, Chief of Staff | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Pamela Wong | officer: Chief Legal Officer | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Shereen Solaiman | officer: Chief People Officer | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Paul Bisaro | director | |
Dale Muzzey | officer: Chief Scientific Officer | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Kevin Richard Haas | officer: Chief Technology Officer | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Natalie Munk | officer: Chief Accounting Officer | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
Lee Nisley Newcomer | director | 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901 |
Rashmi Kumar | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Jayne B. Hart | officer: Executive VP Human Resources | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Jerry S Lanchbury | officer: Senior V.P. - Research | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
From GuruFocus
By Marketwired • 09-19-2023
By GuruFocus Research • 11-04-2023
By GuruFocus Research • 11-06-2023
By Marketwired • 09-06-2023
By GlobeNewswire • 11-09-2023
By Marketwired • 08-17-2023
By Marketwired • 08-15-2023
By Marketwired • 08-07-2023
By Marketwired • 10-26-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.